The potential for ischemic preconditioning to reduce infarct size was first recognized more
than 30 years ago [180]. Despite extension of the concept to ischemic postcondition‑ing …

The translation from numerous successful animal experiments on cardioprotection beyond
that by reperfusion to clinical practice has to date been disappointing. Animal experiments …

In the 30 years since the original description of ischaemic preconditioning, understanding of
the pathophysiology of ischaemia/reperfusion injury and concepts of cardioprotection have …

The translation from mechanistic, more reductionist basic science research to clinical
outcome studies is not a linear, rational process but fraught with many surprises such that …

Adjunctive cardioprotective strategies for ameliorating the reversible and irreversible injuries
with ischemia-reperfusion (I/R) are highly desirable. However, after decades of research, the …

The 30-year anniversary of the discovery of'ischaemic preconditioning'is in 2016. This
endogenous phenomenon can paradoxically protect the heart from acute myocardial …

The mortality from acute myocardial infarction (AMI) remains significant, and the prevalence
of post-myocardial infarction heart failure is increasing. Therefore, cardioprotection beyond …

The possibility that an innate mechanism of myocardial protection might be inducible in the
human heart has generated considerable excitement and enthusiastic research. The …

Coronary heart disease (CHD) is the leading cause of death worldwide. The development of
novel treatment strategies for protecting the myocardium against the detrimental effects of …

Infarct size can be limited by reducing the determinants of infarct size or increasing collateral
blood flow by treatment initiated before the ischaemic event. Reperfusion is the definitive …